HEK293

Agathos Biologics Launches Recombinant Adeno-Associated Virus Production Service Using Novel AE1-BHK Cell Line

Retrieved on: 
Wednesday, March 6, 2024

Agathos Biologics, a leading biotechnology company in genetic medicine, announced today the launch of its recombinant adeno-associated virus (rAAV) production service using the company’s novel proprietary cell line, AE1-BHK.

Key Points: 
  • Agathos Biologics, a leading biotechnology company in genetic medicine, announced today the launch of its recombinant adeno-associated virus (rAAV) production service using the company’s novel proprietary cell line, AE1-BHK.
  • View the full release here: https://www.businesswire.com/news/home/20240305885603/en/
    The AE1-BHK cell line was developed by stable transfection of the BHK-21 (C-13) cell line (ATCC®, catalog number ATCC CCL-10™) with the adenoviral E1 gene.
  • “The launch of our custom rAAV service and the first sale of rAAV made using our AE1-BHK cell line is a significant milestone for the company,” said James Brown, CEO and co-founder of Agathos Biologics.
  • “To our knowledge, this is the first sale of rAAV produced using triple transfection in a cell line other than HEK293.

Applied Biomics Launches Anti-Host Cell Protein (HCP) Antibodies with > 95% Coverage

Retrieved on: 
Thursday, February 29, 2024

Applied Biomics, Inc. , a leading Proteomics service provider, launches a new product line offering Anti-HCP Antibodies with well over 95% coverage.

Key Points: 
  • Applied Biomics, Inc. , a leading Proteomics service provider, launches a new product line offering Anti-HCP Antibodies with well over 95% coverage.
  • View the full release here: https://www.businesswire.com/news/home/20240228749573/en/
    Antibody Coverage of Applied Biomics' Anti-CHO Antibody by 2D Western Blot (WB).
  • Following are highlights of Applied Biomics’ HCP Antibodies:
    High HCP coverage: Detects well over 2500 (up to ~5000) low and high molecular weight (LMW & HMW) HCPs, with > 95% overall HCP coverage and > 90% each quadrant coverage.
  • With our leading HCP antibody coverage services , customers can now test Applied Biomics’ HCP antibody against their process specific HCPs, or compare with other HCP antibodies to find a better fit.

NewBiologix Licenses Florabio’s HEK293 Cell Line for the Generation of Novel and Proprietary Cell Lines for the Stable Expression of rAAVs used in Gene Therapy

Retrieved on: 
Tuesday, February 27, 2024

NewBiologix’s innovative approach stands to replace the industry-standard transient transfection methods, offering a stable, more reliable, and scalable solution for biopharmaceutical companies developing gene therapies.

Key Points: 
  • NewBiologix’s innovative approach stands to replace the industry-standard transient transfection methods, offering a stable, more reliable, and scalable solution for biopharmaceutical companies developing gene therapies.
  • Under the terms of the agreement, NewBiologix acquired rights to use Florabio’s HEK293 suspension cell line for research and commercial applications.
  • Leveraging proprietary genomic data, NewBiologix plans to engineer the Florabio HEK293 cell line and select highly characterized clones with exceptional growth, expansion, and transfectability properties.
  • NewBiologix will achieve its goals faster and more efficiently by starting with the 'FlorabioHEK293' cell line and our chemically defined HEK293 medium.”

Matica Bio Welcomes Four Life Sciences Visionaries as Members of Advisory Board

Retrieved on: 
Tuesday, October 17, 2023

As the inaugural members of Matica Bio’s advisory board, these appointments will provide strategic oversight as the company executes the development, scale-up, and production of CGTs at its purpose-built GMP facility in Texas.

Key Points: 
  • As the inaugural members of Matica Bio’s advisory board, these appointments will provide strategic oversight as the company executes the development, scale-up, and production of CGTs at its purpose-built GMP facility in Texas.
  • Combined with Matica Bio’s bespoke approach to CGT manufacturing – enabled by a fully closed, single-use platform and industry-leading analytical capabilities – the incoming leadership of this newly established advisory board will further empower the company to meet the growing demand for CGT manufacturing expertise.
  • “Matica Bio is thrilled to introduce the accomplished members of our newly formed board of advisors,” said Yun Jeong Song, M.D., president and chief executive officer of Matica Bio.
  • The formation of Matica Bio’s board of advisors comes shortly after the hiring of Laura Parks as head of commercial operations and Heather N. Sugrue as vice president of business development.

New Hope Research Foundation and Forge Biologics Announce cGMP Manufacturing Partnership to Accelerate Gene Therapy for Patients with Tay-Sachs Disease

Retrieved on: 
Wednesday, June 28, 2023

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20230628556153/en/
    “We are proud to be the CDMO partner for New Hope Research Foundation, an organization that is significantly advancing a gene therapy approach to provide hope for patients suffering from Tay-Sachs disease,” said Timothy J. Miller, Ph.D., CEO, President, and Co-Founder of Forge Biologics.
  • “At Forge, we are ready to partner with companies, nonprofit organizations, and gene therapy developers around the world, working towards the mission we share to bring potentially life-saving gene therapies to patients.”
    Through this partnership, Forge will provide adeno-associated virus (AAV) process development, analytical services, and cGMP manufacturing to New Hope Research Foundation.
  • The Foundation will leverage Forge’s platform processes, including its proprietary HEK293 suspension Ignition Cells™, to accelerate the initial production.
  • All development and AAV manufacturing activities will occur at the Hearth, Forge’s 200,000 square foot gene therapy facility in Columbus, Ohio.

Abeona Therapeutics Announces New Preclinical Data from its AAV Ophthalmology Program at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

Retrieved on: 
Tuesday, May 16, 2023

CLEVELAND, May 16, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced new data regarding three internally developed preclinical gene therapy product candidates from its adeno-associated virus (AAV) ophthalmology program that will be presented at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT), taking place from May 16-20, 2023 in Los Angeles, CA.

Key Points: 
  • CLEVELAND, May 16, 2023 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced new data regarding three internally developed preclinical gene therapy product candidates from its adeno-associated virus (AAV) ophthalmology program that will be presented at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT), taking place from May 16-20, 2023 in Los Angeles, CA.
  • Cre-mediated recombination of ABCA4 was confirmed by mRNA sequencing of RNA from transfected HEK293 cells and AAV-dosed animals.
  • RS1 expression was associated with improvement in cone photoreceptor density and increased thickness of the photoreceptor outer nuclear layer.
  • Following intravitreal injection in wild type mice, variants 1 and 7 showed robust protein expression.

Life Biosciences and Forge Biologics Announce cGMP Manufacturing Partnership to Advance Development of Novel Gene Therapies for Aging-Related Diseases

Retrieved on: 
Monday, May 8, 2023

Life Biosciences (“Life Bio”), a biotechnology company advancing innovative cellular rejuvenation technologies to reverse diseases of aging and injury and ultimately restore health for patients, and Forge Biologics (“Forge”), a genetic medicines manufacturing organization, today announced a manufacturing partnership to help advance Life Bio’s partial epigenetic reprogramming platform to address aging-related diseases, including its lead program targeting ophthalmic indications.

Key Points: 
  • Life Biosciences (“Life Bio”), a biotechnology company advancing innovative cellular rejuvenation technologies to reverse diseases of aging and injury and ultimately restore health for patients, and Forge Biologics (“Forge”), a genetic medicines manufacturing organization, today announced a manufacturing partnership to help advance Life Bio’s partial epigenetic reprogramming platform to address aging-related diseases, including its lead program targeting ophthalmic indications.
  • Through this partnership, Forge will provide adeno-associated virus (AAV) process development, toxicology, cGMP manufacturing, and analytical services to Life Bio.
  • All development and AAV manufacturing activities will occur at the Hearth, Forge’s 200,000 square foot gene therapy facility in Columbus, Ohio.
  • “We are delighted to be working with the Forge team, whose expertise in gene therapy manufacturing is unmatched,” said Jerry McLaughlin, Chief Executive Officer of Life Biosciences.

Tenaya Highlights Growing Capabilities in AAV Manufacturing, Capsid Engineering and Expansion into Gene Editing with Six Abstracts Accepted for Presentation at the ASGCT 26th Annual Meeting

Retrieved on: 
Wednesday, May 3, 2023

“Tenaya was founded with a singular focus on developing novel medicines for rare and prevalent forms of heart disease.

Key Points: 
  • “Tenaya was founded with a singular focus on developing novel medicines for rare and prevalent forms of heart disease.
  • “The presentations at this year’s ASGCT highlight innovations in manufacturing, capsid engineering and gene editing, that support the advancement of our current pipeline and create new opportunities for future pipeline candidates.
  • At ASGCT, Tenaya researchers will present data detailing the scale up, formulation and purification techniques deployed in the successful initial manufacture of TN-201.
  • AAV9 is the current capsid of choice for cardiovascular indications and the capsid being used in Tenaya’s TN-201 and TN-401 gene therapy product candidates.

Catalent Expands UpTempo ℠ AAV Platform to Accelerate Development of Gene Therapies

Retrieved on: 
Thursday, March 9, 2023

SOMERSET, N.J., March 9, 2023 /PRNewswire-PRWeb/ -- Catalent, the leader in enabling the development and supply of better treatments for patients worldwide, today announced the expansion of its UpTempo ℠  platform process for the development and CGMP manufacturing of adeno-associated viral (AAV) vectors. The platform now includes an in-house, clonal HEK293 cell line, and off-the-shelf plasmids to support a robust supply chain for the development and manufacture of gene therapies, and the reduction of timelines to first-in-human clinical evaluation.

Key Points: 
  • Catalent, the leader in enabling the development and supply of better treatments for patients worldwide, today announced the expansion of its UpTempo ℠ platform process for the development and CGMP manufacturing of adeno-associated viral (AAV) vectors.
  • The platform now includes an in-house, clonal HEK293 cell line, and off-the-shelf plasmids to support a robust supply chain for the development and manufacture of gene therapies, and the reduction of timelines to first-in-human clinical evaluation.
  • SOMERSET, N.J., March 9, 2023 /PRNewswire-PRWeb/ -- Catalent, the leader in enabling the development and supply of better treatments for patients worldwide, today announced the expansion of its UpTempo ℠ platform process for the development and CGMP manufacturing of adeno-associated viral (AAV) vectors.
  • "Speed to patients is paramount for gene therapy innovators, and as such, we've seen multiple customers requesting and signing up for the UpTempo platform.

Matinas BioPharma Provides Business Update and 2023 Strategic Outlook

Retrieved on: 
Monday, January 30, 2023

ET

Key Points: 
  • ET
    BEDMINSTER, N.J., Jan. 30, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE AMER: MTNB, Matinas), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform technology, today is providing a business update on its ongoing programs and discussing its strategic outlook for 2023.
  • Our ongoing collaborations with BioNTech and, recently, National Resilience, have aligned Matinas with two of the world’s leading companies in the gene therapy space.
  • The Company will host a live conference call and webcast to discuss this corporate update and 2023 business outlook today, Monday, January 30 at 4:30 p.m.
  • The live webcast will be accessible on the Investors section of Matinas BioPharma’s website, www.matinasbiopharma.com , and archived for 90 days.